The latest news on Sysmex Inostics and OncoBEAM™
Inostics’ blood test, based on BEAMing Digital PCR technology, yielded a more informative summary of cancer mutations than a traditional biopsy. These findings come from a subanalysis of the phase III GIST–Regorafenib In Progressive Disease (GRID) trial presented at the AACR Annual Meeting 2013, held in Washington D.C., April 6-10.
Researchers compared whether BEAMing technology or traditional tissue analysis was better at detecting secondary resistance mutations in the KIT gene emerging after the disease had become resistant to imatinib and sunitinib. The BEAMing technology proved far superior, finding such mutations in 48 percent of the blood samples, compared to only 12 percent found in tissue samples.Back to news and press releases